Listed

20/20 Biolabs, Inc.

AIDXNasdaqCIK 1139685IndustrialsFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$730.6k, Q2 FY2026
Operating income−$1.2m, Q2 FY2026
Net income−$1.5m, Q2 FY2026
20/20 Biolabs, Inc., income statement, quarterly
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Revenue$k554Revenue, period not labelled, three months to 2025-03-31$553.8k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure535Revenue, period not labelled, three months to 2025-06-30$535.1k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure353Revenue, Q1 FY2026, three months to 2026-03-31$353.4k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure731Revenue, Q2 FY2026, three months to 2026-06-30$730.6k. XBRL concept us-gaap:Revenues. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Cost of revenue$k388Cost of revenue, period not labelled, three months to 2025-03-31$388.0k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure372Cost of revenue, period not labelled, three months to 2025-06-30$371.8k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure290Cost of revenue, Q1 FY2026, three months to 2026-03-31$290.5k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure426Cost of revenue, Q2 FY2026, three months to 2026-06-30$425.8k. XBRL concept us-gaap:CostOfRevenue. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Gross profit$k166Gross profit, period not labelled, three months to 2025-03-31$165.8k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure163Gross profit, period not labelled, three months to 2025-06-30$163.3k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure62.9Gross profit, Q1 FY2026, three months to 2026-03-31$62.9k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure305Gross profit, Q2 FY2026, three months to 2026-06-30$304.7k. XBRL concept us-gaap:GrossProfit. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Research and development$k137Research and development, period not labelled, three months to 2025-03-31$136.8k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure194Research and development, period not labelled, three months to 2025-06-30$194.1k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure153Research and development, Q1 FY2026, three months to 2026-03-31$153.5k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure258Research and development, Q2 FY2026, three months to 2026-06-30$257.6k. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Selling, general and administrative$k801Selling, general and administrative, period not labelled, three months to 2025-03-31$801.1k. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure815Selling, general and administrative, period not labelled, three months to 2025-06-30$814.8k. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure1,353Selling, general and administrative, Q1 FY2026, three months to 2026-03-31$1.4m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure1,291Selling, general and administrative, Q2 FY2026, three months to 2026-06-30$1.3m. XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Operating income$k(772)Operating income, period not labelled, three months to 2025-03-31−$772.2k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure(846)Operating income, period not labelled, three months to 2025-06-30−$845.7k. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure(1,443)Operating income, Q1 FY2026, three months to 2026-03-31−$1.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure(1,244)Operating income, Q2 FY2026, three months to 2026-06-30−$1.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Interest expense$k0.7Interest expense, period not labelled, three months to 2025-03-31$740. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure0.9Interest expense, period not labelled, three months to 2025-06-30$935. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure267Interest expense, Q1 FY2026, three months to 2026-03-31$267.0k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure272Interest expense, Q2 FY2026, three months to 2026-06-30$272.2k. XBRL concept us-gaap:InterestExpenseNonoperating. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Net income$k(765)Net income, period not labelled, three months to 2025-03-31−$764.6k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure(841)Net income, period not labelled, three months to 2025-06-30−$840.9k. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure(2,175)Net income, Q1 FY2026, three months to 2026-03-31−$2.2m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure(1,506)Net income, Q2 FY2026, three months to 2026-06-30−$1.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Diluted EPS$ per share(0.16)Diluted EPS, period not labelled, three months to 2025-03-31−$0.16 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure(0.17)Diluted EPS, period not labelled, three months to 2025-06-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure(0.28)Diluted EPS, Q1 FY2026, three months to 2026-03-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure(0.26)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Basic EPS$ per share(0.16)Basic EPS, period not labelled, three months to 2025-03-31−$0.16 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure(0.17)Basic EPS, period not labelled, three months to 2025-06-30−$0.17 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure(0.28)Basic EPS, Q1 FY2026, three months to 2026-03-31−$0.28 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure(0.26)Basic EPS, Q2 FY2026, three months to 2026-06-30−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure

Balance sheet

Cash and equivalents$4.5m, Q2 FY2026
Shareholders' equity$1.6m, Q2 FY2026
20/20 Biolabs, Inc., balance sheet, quarterly
Line itemUnitperiod not labelled2023-12-31period not labelled2024-12-31period not labelled2025-03-31period not labelled2025-06-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$knot reported1,784Cash and equivalents, period not labelled, at 2024-12-31$1.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-03-31, accession 0001213900-26-037667.Report this figurenot reportednot reported1,026Cash and equivalents, FY2025, at 2025-12-31$1.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure4,219Cash and equivalents, Q1 FY2026, at 2026-03-31$4.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure4,546Cash and equivalents, Q2 FY2026, at 2026-06-30$4.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Current assets$knot reported2,034Current assets, period not labelled, at 2024-12-31$2.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-03-31, accession 0001213900-26-037667.Report this figurenot reportednot reported1,471Current assets, FY2025, at 2025-12-31$1.5m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure4,700Current assets, Q1 FY2026, at 2026-03-31$4.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure5,076Current assets, Q2 FY2026, at 2026-06-30$5.1m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Total assets$knot reported3,584Total assets, period not labelled, at 2024-12-31$3.6m. XBRL concept us-gaap:Assets. 10-K filed 2026-03-31, accession 0001213900-26-037667.Report this figurenot reportednot reported4,137Total assets, FY2025, at 2025-12-31$4.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure5,803Total assets, Q1 FY2026, at 2026-03-31$5.8m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure6,123Total assets, Q2 FY2026, at 2026-06-30$6.1m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Current liabilities$knot reported1,355Current liabilities, period not labelled, at 2024-12-31$1.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-03-31, accession 0001213900-26-037667.Report this figurenot reportednot reported2,463Current liabilities, FY2025, at 2025-12-31$2.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure2,580Current liabilities, Q1 FY2026, at 2026-03-31$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure2,551Current liabilities, Q2 FY2026, at 2026-06-30$2.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Total liabilities$knot reported2,079Total liabilities, period not labelled, at 2024-12-31$2.1m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-03-31, accession 0001213900-26-037667.Report this figurenot reportednot reported4,157Total liabilities, FY2025, at 2025-12-31$4.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure3,046Total liabilities, Q1 FY2026, at 2026-03-31$3.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure2,964Total liabilities, Q2 FY2026, at 2026-06-30$3.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure
Shareholders' equity$k4,287Shareholders' equity, period not labelled, at 2023-12-31$4.3m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-03-31, accession 0001213900-26-037667.Report this figure1,505Shareholders' equity, period not labelled, at 2024-12-31$1.5m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure1,063Shareholders' equity, period not labelled, at 2025-03-31$1.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure352Shareholders' equity, period not labelled, at 2025-06-30$351.6k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure(19.2)Shareholders' equity, FY2025, at 2025-12-31−$19.2k. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure2,553Shareholders' equity, Q1 FY2026, at 2026-03-31$2.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure1,621Shareholders' equity, Q2 FY2026, at 2026-06-30$1.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure

Cash flow

Operating cash flow−$605.5k, Q2 FY2026
20/20 Biolabs, Inc., cash flow, quarterly
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$k(488)Operating cash flow, period not labelled, three months to 2025-03-31−$488.3k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure(534)Operating cash flow, period not labelled, three months to 2025-06-30−$534.1k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001213900-26-090042. Derived: 6-month figure less the 3-month figure.Report this figure(1,289)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$1.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure(605)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$605.5k. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001213900-26-090042. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)10.79m, Q2 FY2026
20/20 Biolabs, Inc., shares, quarterly
Line itemUnitperiod not labelled2025-03-31period not labelled2025-06-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares4.8Diluted shares (weighted), period not labelled, three months to 2025-03-314,823,125 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure4.8Diluted shares (weighted), period not labelled, three months to 2025-06-304,823,125 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure7.7Diluted shares (weighted), Q1 FY2026, three months to 2026-03-317,657,229 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-20, accession 0001213900-26-059542.Report this figure10.8Diluted shares (weighted), Q2 FY2026, three months to 2026-06-3010,790,722 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure

Shares outstanding: 12.77mShares outstanding, period not labelled, at 2026-08-1412,770,303 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001213900-26-090042.Report this figure at Aug 14, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. Listed shows no prices and gives no investment advice.